脉冲性耳的原因和治疗选择
Badih J Daou1, Andrew F Ducruet1
1Department of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA.
Neurosurgery clinics of North America
|May 23, 2024
概括
脉冲性耳声 (PT) 可能源于结构性静脉异常. 内血管治疗,如支架和栓塞,为经过精心挑选的患有这些疾病的患者提供安全有效的缓解.
科学领域:
- 神经学 神经学
- 血管外科 血管外科
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
背景情况:
- 脉冲性耳声 (PT) 需要对结构原因进行彻底的调查.
- 神经成像技术的进步越来越多地确定了与PT相关的结构性静脉异常.
- 几种静脉异常会破坏听觉结构的血液流动,导致PT.
研究的目的:
- 审查导致脉动性耳的结构性静脉异常.
- 讨论PT的内血管治疗的作用.
主要方法:
- 在PT患者中神经成像发现的文献综述.
- 对导致PT的静脉异常进行内血管治疗方式的分析.
主要成果:
- 持续性动脉静脉,异常性内高血压,鼻狭窄,西格状鼻壁异常,状静脉异常和缩的发射静脉都与此有关.
- 内血管治疗方法 (支架,线圈,栓塞) 显示出高的疗效和安全性.
- 在适当选择的患者中,可以实现症状缓解.
结论:
- 结构性静脉异常是脉动性耳的重要原因之一.
- 内血管干预为PT提供了有效的治疗选择.
- 仔细的患者选择对于成功的内血管治疗至关重要.
相关概念视频
Increased pulse rate
652
Tachycardia is a condition marked by an abnormally fast or irregular heart rate, surpassing the typical resting rate. In adults, tachycardia is characterized by a pulse rate ranging from 100 to 180 beats per minute. The increased heart rate can result in inadequate blood flow to various body parts, ultimately diminishing the oxygen supply to organs and tissues.
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
652
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
157
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
157
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
146
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
146
Tonsillitis II: Management
110
This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
110
Angle Closure Glaucoma: Treatment
479
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
479
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
155
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
155


